NCT02148627View on ClinicalTrials.gov

Safety Study of LY3041658 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 16, 2014

Primary Completion Date

February 11, 2017

Study Completion Date

February 11, 2017

Conditions
Healthy
Interventions
DRUG

LY3041658 (SC)

Administered SC

DRUG

LY3041658 (IV)

Administered as slow IV infusion

DRUG

Placebo

Administered as slow IV infusion

Trial Locations (2)

21225

PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore

90216

Parexel Early Phase Unit at Glendale, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02148627 - Safety Study of LY3041658 in Healthy Participants | Biotech Hunter | Biotech Hunter